Buy Thymosin Alpha 1 Thymosin Alpha 1 (Tα1), also known as Zadaxin or Thymalfasin, is a naturally occurring 28-amino acid peptide hormone produced by the thymus gland. It plays a key role in modulating the immune system, particularly by enhancing T-cell function and promoting immune balance. Synthetic versions are used therapeutically. Key Biological Functions Immune Modulation: Stimulates differentiation and maturation of T-cells (including CD4 helper T-cells, CD8 cytotoxic T-cells, and natural killer cells). It boosts cytokine production (e.g., IL-2, IFN-γ) without causing excessive inflammation. Antiviral Effects: Enhances antiviral immunity by improving dendritic cell function and antigen presentation. Anti-Cancer Potential: Supports anti-tumor immunity by activating immune cells against cancer. Evidence: Derived from thymosin fraction 5 (isolated in the 1960s by Allan Goldstein). Human studies show it restores thymic function in immunocompromised states (e.g., HIV, chemotherapy). Medical Uses and Approvals Condition Status Key Evidence Chronic Hepatitis B & C Approved in over 35 countries (e.g., China, Italy, Russia as Zadaxin). Meta-analyses (e.g., World J Gastroenterol 2012) show improved response rates with IFN-α combo therapy; HBsAg clearance in 20-30% of cases. COVID-19 Investigational; used in trials (e.g., China 2020). Phase III trials (Front Immunol 2021) reported reduced mortality (OR 0.30) and faster viral clearance in severe cases. Cancer (e.g., Melanoma, Lung) Adjunctive therapy. Improves survival in combo with chemo/immunotherapy (J Immunother 2019); enhances PD-1 inhibitor efficacy. Immunodeficiencies** (HIV, Sepsis) Off-label/research. Restores CD4 counts; Phase II trials show sepsis survival benefit (Crit Care Med 2014). Vaccines Adjuvant. Boosts antibody responses (e.g., flu vaccine trials). Dosage: Typically 1.6 mg subcutaneous injection, 2x/week for 6 months (varies by indication). Half-life ~2 hours. Mechanism of Action Tα1 binds Toll-like receptors (TLR-2/9) on antigen-presenting cells, upregulating MHC class I/II and costimulatory molecules. It doesn’t directly kill pathogens but amplifies adaptive immunity. Molecular Structure: Copy code Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Glu-Glu-Asp-OH (SEQ ID: 28 aa, MW ~3108 Da) Side Effects and Safety Common: Mild injection-site reactions (redness, pain). Rare: Fatigue, nausea (<5% incidence). Contraindications: Hypersensitivity; caution in autoimmunity (theoretical risk of overactivation). Safety Data: Well-tolerated in 20 years of use; no genotoxicity or teratogenicity in preclinical studies (FDA IND status). Availability and Legality Prescription: Not FDA-approved in the US (available via compounding pharmacies or research peptides). Research: Widely studied (PubMed: 1,500 papers). Ongoing trials for Lyme disease, TB, and post-viral fatigue. Peptide Therapy Context: Popular in functional medicine for “immune reboot” (e.g., 5-10 mg/week cycles), often stacked with BPC-157 or TB-500. Recent Research Highlights Long COVID: Italian trial (Infectious Disease Reports 2023) showed symptom resolution in 80% vs. 40% placebo. Cancer Immunotherapy: Synergy with checkpoint inhibitors (Cancer Immunol Res 2022). Aging: Restores thymic output in elderly (Aging Cell 2020). For sourcing or personal use, consult a physician—it’s not a DIY supplement. Sources: ClinicalTrials.gov, PubMed, SciDirect. If you have a specific question (e.g., dosing protocols, studies), let me know!
